I'm think BMY came around to look at the prostate results and stayed to talk about possibilities. If prostate results are looking even better then combo cervical I think we opted to go with BMY instead of AZN. After all Opdivo is basically Keytruda.
That's what I'm afraid of too. There's got to be a reason for investors' lack of interest in ADXS. And ADXS's silence doesn't make me feel any better. They need to put out good news, the soon the better.